ArticleCancer immunology, immunotherapy : CII2022

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.

Eliza Guti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.